ACOTEC SCIEN.H. DL-00001 (7W3) - Total Assets
Based on the latest financial reports, ACOTEC SCIEN.H. DL-00001 (7W3) holds total assets worth €1.87 Billion EUR (≈ $2.18 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check how aggressively does ACOTEC SCIEN.H. DL-00001 reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
ACOTEC SCIEN.H. DL-00001 - Total Assets Trend (2021–2025)
This chart illustrates how ACOTEC SCIEN.H. DL-00001's total assets have evolved over time, based on quarterly financial data. Check ACOTEC SCIEN.H. DL-00001 earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
ACOTEC SCIEN.H. DL-00001 - Asset Composition Analysis
Current Asset Composition (December 2025)
ACOTEC SCIEN.H. DL-00001's total assets of €1.87 Billion consist of 71.6% current assets and 28.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 21.4% |
| Accounts Receivable | €220.49 Million | 11.8% |
| Inventory | €126.95 Million | 6.8% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €105.99 Million | 5.7% |
| Goodwill | €1.15 Million | 0.1% |
Asset Composition Trend (2021–2025)
This chart illustrates how ACOTEC SCIEN.H. DL-00001's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 7W3 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ACOTEC SCIEN.H. DL-00001's current assets represent 71.6% of total assets in 2025, a decrease from 95.1% in 2021.
- Cash Position: Cash and equivalents constituted 21.4% of total assets in 2025, down from 87.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 11.8% of total assets.
ACOTEC SCIEN.H. DL-00001 Competitors by Total Assets
Key competitors of ACOTEC SCIEN.H. DL-00001 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $90.55 Million |
|
Medacta Group SA
SW:MOVE
|
Switzerland | CHF860.76 Million |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.52 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
Xiangyu Medical Co. Ltd. A
SHG:688626
|
China | CN¥3.27 Billion |
|
INKON Life Technology Co Ltd
SHE:300143
|
China | CN¥4.17 Billion |
ACOTEC SCIEN.H. DL-00001 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.73 | 8.98 | 6.84 |
| Quick Ratio | 5.19 | 7.82 | 6.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.10 Billion | €1.08 Billion | €1.11 Billion |
ACOTEC SCIEN.H. DL-00001 - Advanced Valuation Insights
This section examines the relationship between ACOTEC SCIEN.H. DL-00001's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.60 |
| Latest Market Cap to Assets Ratio | 0.16 |
| Asset Growth Rate (YoY) | 12.4% |
| Total Assets | €1.87 Billion |
| Market Capitalization | $304.44 Million USD |
Valuation Analysis
Below Book Valuation: The market values ACOTEC SCIEN.H. DL-00001's assets below their book value (0.16x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: ACOTEC SCIEN.H. DL-00001's assets grew by 12.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ACOTEC SCIEN.H. DL-00001 (2021–2025)
The table below shows the annual total assets of ACOTEC SCIEN.H. DL-00001 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €1.87 Billion ≈ $2.18 Billion |
+12.36% |
| 2024-12-31 | €1.66 Billion ≈ $1.94 Billion |
+3.20% |
| 2023-12-31 | €1.61 Billion ≈ $1.88 Billion |
+14.22% |
| 2022-12-31 | €1.41 Billion ≈ $1.65 Billion |
+7.89% |
| 2021-12-31 | €1.31 Billion ≈ $1.53 Billion |
-- |
About ACOTEC SCIEN.H. DL-00001
Acotec Scientific Holdings Limited operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China and internationally. The company's products include AcoArt Orchid & Dhalia, a paclitaxel DCB used to prevent stenosis or occlusion in superficial femoral artery and popliteal artery for the treatment of lower extremity artery disease with… Read more